Help Therapeutics, a Nanjing, China-based iPSC therapeutics leading global platform company, raised USD25m in Series C financing.
The round was led by Ming Bioventures, followed by Share Capital, Beisen Medical Fund, and Jolmo Capital, with participation from shareholder Purple Bull Startups, and Hoyue Capital.
The company intends to use the funds to conduct and complete clinical trials of its fully independent intellectual property development pipeline, iPSC heart cell injection, and will initiate clinical studies of immune cell therapy based on iPSC technology within the next year.
Founded by Dr. Wang Jiaxian, Help Therapeutics has the first induced pluripotent stem cell (iPSC) biospecimen bank authorized by the Ministry of Science and Technology for the preservation of human genetic resources in China. Entrusted by the National Human Genetic Resources Sharing Service Platform and as the only officially recognized iPSC rare disease cell bank in the National 14th Five-Year Plan (National Science and Technology Heritage Office [2021]-BC0022), Help Therapeutics carries the responsibility of human genetic material and makes every effort to promote the role of China’s iPSC technology platform and rare disease research and development treatment. The company will provide high-quality and diversified biological samples to research institutions and enterprises, accelerate rare disease research and orphan drug development, and help the rapid development of iPSC cell industry.
Help Therapeutics has laid out several R&D pipelines in the areas of heart failure and tumor immunity, among which iPSC technology therapy for the treatment of moderate to severe heart failure has entered several authoritative centers nationwide to conduct large-scale randomized controlled human clinical trials.
FinSMEs
29/11/2021